Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Shares of Novavax Inc. NVAX slid 3.18% to $7.92 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.18% to 17,436.10 ...
Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.
Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed ...
NVAX opened at $7.92 on Friday. The stock’s fifty day simple moving average is $8.46 and its 200 day simple moving average is $9.71. Novavax has a 1-year low of $3.81 and a 1-year high of $23.86 ...
(RTTNews) - Novavax, Inc. (NVAX) announced Tuesday that James Young is retiring as Chair of the Board and Margaret McGlynn has been appointed as his successor. The Company also appointed John ...
14d
Stocktwits on MSNNovavax Lands Wall Street 'Buy' Rating After Q4 Results, Retail Bulls Eye More Upside On Sanofi PartnershipNovavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and cost-cutting measures reassured investors. The momentum was aided by BTIG ...
Bullish option flow detected in Novavax (NVAX) with 10,455 calls trading, 2x expected, and implied vol increasing over 6 points to 78.51%. 3/14 ...
Market forces rained on the parade of Novavax, Inc. (NASDAQ:NVAX) shareholders today, when the analysts downgraded their forecasts for this year. Both revenue and earnings per share (EPS) forecasts ...
As sales of its COVID vaccine plummet, Novavax is looking ahead toward other novel vaccines, brought to market with the help ...
Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...
B. Riley decreased their FY2024 earnings estimates for Novavax in a report issued on Thursday, February 20th. B. Riley analyst M. Mamtani now anticipates that the biopharmaceutical company will post ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results